



# **COVID-19 Initiative**

# CanPath brings together seven cohorts across ten provinces





# CanPath captures a broad range of data to enable the study of health and disease



CanPath is **linking personal**, **behavioural**, **environmental**, **health system and biological data** to investigate cancer and chronic disease causes and determinants.



# Data linkages enable us to evaluate our cohort in real-time



### CanPath COVID-19 Initiative

- Leverages existing infrastructure to determine population-level prevalence of COVID-19;
- Determine biological, societal and behavioural factors that affect susceptibility to COVID-19;
- Capture the socio-economic and mental health and long-term health outcomes of COVID-19


CanPath is a member of <u>The COVID-19 Host Genetics Initiative</u>



# SUPPORT-Canada: A national COVID-19 serological surveillance study











Collection of COVID-19 related data and outcomes from over 100,000 Canadians



Longitudinal serological surveillance of SARS-CoV-2 antibodies in diagnosed, symptomatic, asymptomatic and susceptible Canadians



Deep sequencing to support functional immunogenomics studies

# CanPath COVID-19 questionnaire was designed to align with international efforts



COVID-19 test result/ suspected infection



Symptoms experienced (if any)



Participant hospitalized or received medical care



Current health status and risk factors for COVID-19



Potential source of exposure




Impact of pandemic on job status



Impact of the pandemic on mental, emotional, social and financial wellbeing

# **CanPath COVID-19 questionnaire timeline**



# Over 95,000 questionnaires completed nationally

COVID-19 Questionnaires Completed as of October 31, 2020:















15,560

19,117

774

41,766

7,779

10,518

Harmonized questionnaire data will be available for researchers by the end of the calendar year.

## **Preliminary results from COVID-19 Qx**

### Harmonized Data from 93,119 CanPath participants

Median age: 63 years old

Percentage tested for COVID-19: 11.5% (n = 10,710)

Percentage testing positive for COVID-19: 0.21% (n = 195)

Percentage hospitalised from COVID-19: 0.02% (n = 21)

Suspected undiagnosed cases (self-reported): 2.66% (n = 2,479)

Percentage experiencing mild or severe symptoms: 52.2% (n = 48,570)

Percentage reporting a change in employment status: **25.4%** (n = 23,623)


# CARTaGENE published first summary article in <a href="mailto:medRxiv">medRxiv</a> (Sept 1)

#### **RESEARCH**

Epidemiological and socio-economic characteristics of the COVID-19 spring outbreak in Quebec, Canada: A population-based study

Rodolphe Jantzen<sup>1,2\*</sup>, Nolwenn Noisel<sup>1,2</sup>, Sophie Camilleri-Broët<sup>3</sup>, Catherine Labbé<sup>1</sup>, Thibault de Malliard<sup>1</sup>, Yves Payette<sup>1</sup> and Philippe Broët<sup>1,2,4,5</sup>

## **Canada Coronavirus Map and Case Count**





Used social distancing when out in public

94%



Washed hands more regularly

93%



Avoided crowds and large gatherings

92%



Avoided leaving the house for non-essential reasons

88%



Did not visit with people outside household

75%



Wore a mask when going out in public

73%



Avoided touching face

71%



Stocked up on essentials at 66% grocery store or pharmacy



Worked from home where that was an option

39%



Wore gloves when going out in public

26%


### Precautions taken


### Some precautions vary by groups:

### Women are more likely to:

- wear masks (75% vs 69%)
- stay home (90% vs 84%)
- stock-up on essentials (69% vs 61%)
- avoid visiting with people outside the home (77% vs 71%)

## Precautions taken by all cohorts






### Racial inequities of COVID-19




 Ethnic minorities were 2.1x more likely to be infected (95% CI: 1.34 – 3.14)




### **Racial inequities of COVID-19**

#### Socio-economic factors




### **Gender Gaps**





- Nationwide women are overrepresented in industries hospitality and food services, retail trade, educational services, health care and social assistance most affected by closures, earnings losses and layoffs
- 61% of the essential workers are women
- Men and women have similar odds of contracting the virus:  $OR_{\text{women vs. men}} = 1.2$  (95% CI: 0.82 1.85) but men face a higher risk of death, across the globe

## CanPath

### Impact on cancer patients' access to health care







## Symptoms, exposures and COVID-19 positivity

#### Covid +ve:

86% fatigue

83% shortness of breath

82% loss of taste


80% fever

80% headache

78% loss of smell

60% dry cough






Symptom or Exposure n= 4,703 (11.2%) tested in OHS and 102 (2.2%) were positive	Odds Ratio (95% CI) Infection (+ve test)
Loss of smell (ref: no loss of smell, no fever, no headache)	78.3 (42.20 - 145.10)
Loss of smell & headache (ref: no loss of smell, no fever)	101.80 (54.63 - 189.69)
Loss of taste	27.35 (3.5 - 212.92)
Fever (ref: no loss of smell, no headache)	12.0 (6.12 - 23.41)
Contact with a COVID-19 case	41.74 (27.81 - 62.67)
Medical worker	6.50 (4.20 - 10.0)

### Blood type and COVID-19 susceptibility

- Current body of evidence suggests that O and Rh- blood types may protect against infection, and possibly, severe COVID-19 illness
- SARS-CoV-2 may be reacting differently to surface factors and antibodies

Blood type	N	%	Odds Ratio (95% CI)	
			Infection	Hospitalization
Α	9651	35%	1.12 (0.66 - 1.92)	0.66 (0.14 - 3.07)
AB	1678	6%	0.48 (0.27 - 0.60)	-
В	3793	14%	1.60 (0.85 - 3.03)	0.39 (0.04 - 3.51)
0	12549	45%	Referent	Referent



 Effect size seen in other studies is small and shouldn't undermine importance of other public health and therapeutic measures

### **Risk factors for severe COVID-19**


Risk factors	N	%	Odds Ratio (95% CI)  Hospitalization
Older age (≧ 65 years)	18021	43&	2.19 (0.64 - 7.43)
CVD	11598	28%	3.66 (1.05 - 12.81)
Obesity (BMI ≧ 30.0)	9204	25%	3.50 (1.00 - 12.21)


- immune response to the viral infection key and immune function declines with age
- chronic health conditions have been associated with increased risk
- obesity is the most significant risk factor, after only older age, for being hospitalized



### Long-term effects of COVID-19 infection

- Most recover completely within a few weeks
  - 77% recovered mostly or completely
  - those not fully recovered reported persistent difficulties, some for more than 30 days, with 2-16 symptoms






### Long-term effects of COVID-19 infection

- Long-term sequelae unknown
- General: chronic fatigue, rashes
- Neurological: cognitive problems, brain fog, insomnia, persistent loss of smell and taste, possible ↑ risk of Parkinson's or Alzheimer's
- Cardiac: myocarditis, heart failure
- Lungs: long-term breathing difficulty
- Mental health: post-traumatic stress syndrome, anxiety and depression



# Administrative health linkages can be completed within regional cohorts




## Multi-Region Data Linkage through HDRN

CanPath and Health Data Research Network Canada (HDRN Canada) are partnering to facilitate multi-jurisdictional linkage between CanPath cohorts and regional data holders through the Data Access Support Hub (DASH)

DASH is one of the first initiatives of HDRN Canada, which is made up of provincial, territorial and federal organizations which hold and manage data.


**DASH** is a single-stop online portal for requesting access to multi-jurisdictional Canadian data, and includes:

- An inventory of 380+ datasets available for request
- 140+ multi-jurisdictional algorithms
- An inventory of data access processes at HDRN Canada sites






# Linkage of the OHS with ICES' data holdings




# Linkage of the OHS to the Ontario Lab Information System (OLIS)



- # positive tests = 535
- # unique tests conducted = 47,993
- % positive = 1.11%



# Linkage of the OHS to the Ontario Lab Information System (OLIS)



# tests conducted = 91, 938 # unique tests conducted = 47,993 Mean # tests per participant = 1.9 Range in # tests = 1 - 32

## CanPath COVID-19 Serological Studies

### **CIHR-funded study**

- \$2.1 million plus an additional \$500k top-up from CITF
- Seroprevalence of SARS-CoV-2 antibodies in 3,000 randomly selected CanPath participants at 3 time points (500 per regional cohort)
- Developing capacity for immunogenomics through blood collection from 4,000 participants

### **COVID-19 Immunity Task Force-funded Study**

- \$1.9 million in Phase 1 funding
- Seroprevalence of SARS-CoV-2 antibodies in 20,000 targeted CanPath participants
- Includes populations that are traditionally not included in studies or are among the highest risk of exposure to COVID-19, such as residents of long-term care homes and people living in under-served urban and rural communities with high prevalence of COVID-19

Both studies will collect dried blood spots using kits mailed to participants.



## **Serological Study Questionnaire**

### Unique variables not collected in initial COVID-19 Questionnaire

- More detailed job classifications for front-line workers likely to have occupational exposures:
  - Passenger and delivery drivers, including taxi/uber drivers, restaurant and package delivery drivers
  - Services requiring entry into private homes, including Personal Support Workers, nurses, community aid/shelter workers, tradespeople, movers and cleaners
- COVID-19 Vaccines:
  - Participant vaccination status (which one and date), vaccine availability, and willingness to receive COVID-19 vaccine









### **COVID-19 Host Genetics Initiative**

Brings together the human genetics community to generate, share and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity and outcomes

195 contributing studies from around the world are seeking to:


- 1. Provide an environment to foster the sharing of resources to facilitate COVID-19 host genetics research (e.g. protocols, questionnaires);
- 2. Organize analytical activities across studies to identify genetic determinants of COVID-19 susceptibility and severity;
- 3. Provide a platform to share the results from meta-analytical activities to benefit the broader scientific community.




### **COVID-19 Host Genetics Initiative**

Brings together the human genetics community to generate, share and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity and outcomes

Genome-wide Association Study of Severe Covid-19 with Respiratory Failure (David Ellinghaus, D. et al. 2020. NEMJ.)









## **Accessing CanPath Data**

portal.canpath.ca





Find out more about the five regional cohorts of the CanPath.

Read More

Data



Find out more about the CanPath datasets and data harmonization approach.

Read More **Biosamples** 



Find out more about CanPath's biologicalsample collection and its upcoming availability. Read More Access



Find out more about CanPath Access Policy, the access process, and approved research projects.

Read More

## **Accessing CanPath Data**

### portal.canpath.ca

English / Français News & Events

Register | Login

Home Cohort Data Biosamples Access - Search Contact Us





#### **CORE DATA**

The core harmonized data includes information related to health and risk factors, mental health, physical measures and biological samples collected by the British Columbia Generations Project, Alberta's Tomorrow Project, Ontario Health Study, CARTaGENE (Quebec), Atlantic Partnership for Tomorrow's Health Study and Manitoba Tomorrow Project as core CanPath data content. The Manitoba Tomorrow Project is currently in recruitment and participant data is not yet ready for research.

Read more

2,353 Harmonized Variable



#### **GENOTYPE DATA**

Genotype data on more than 4,800 CanPath participants is now available for access. The genotype data provides information on over 820,000 SNPs (Affymetrix UK Biobank Axiom® 2.0 gene chip). Marker categories include disease markers, pharmacogenomics, Human Leukocyte Antigen (HLA), inflammation and Expression quantitative trait loci (eQTL) variants. This work was completed with the assistance of:

- The Clinical Genomic Centre, Mount Sinai Hospital, Toronto, Canada (Genotyping and DNA preparation);
- Genome Quebec Biobank, Ecogene-21 Biocluster, Saguenay, Canada (DNA preparation); and,
- Ontario Institute for Cancer Research, Toronto, Canada (Data Analysis).

Funding was provided by the Canadian Partnership Against Cancer.

Read more



#### **ENVIRONMENTAL EXPOSURE DATA**

The CIHR-funded Canadian Urban Environmental Health Research Consortium (CANUE) collates and generates standardized area-level environmental data on air and noise pollution, land use, green/natural spaces, climate change/extreme weather, and socioeconomic conditions and links this data to existing Canadian cohort studies and administrative health databases. An initial batch of CANUE exposure datasets have been merged with the national harmonized CanPath dataset and are now available to researchers. These datasets include:

Canadian Active Living Environments Database (Can-ALE)



## **Accessing CanPath Data**

#### **My Access Requests**

**▲** New Access Request

<u>Save</u> <u>Valida</u>

#### **SCHEDULE A**

#### CanPath Data and Biosamples Access Application Form

This Access Application Form is to be used by all researchers seeking access to Research Data and/or Biosamples, referred to as Material in the Data and Material Sharing Agreement. Please refer to the CanPath Access Policy for the meaning of all capitalized terms used in this form, which is available on the CanPath portal.

Applicants should review the Access Policy , Publications Policy and Intellectual Property Policy in the CanPath Policies & Guidelines Section (Access Process Page) before completing this Access Application Form.

Applicants must complete all mandatory sections and provide supporting documentation before the access request will be considered. Further information on CanPath's review and approval process can be found in the Access Policy.

Upon approval of an access request by the Access Committee, access to Research Data and/or Material will be granted for the timeframe set out in the approved Access Application Form and the Access Agreement. An Annual Progress Report must be completed to access and use Research Data and/or Material beyond a one-year period.


The title of the Approved Research Project, name(s) of the Approved User and Research Team involved, their status and credentials, name(s) of the Approved Institution(s), and a lay summary of the scientific abstract submitted by the Applicant will be added to the public CanPath Access Registry.

#### I - Contact and Research Project Information


#### A. Name, institution, and contact details of the Applicant (Principal Applicant)



### **Access Process Overview**



### **Expedited COVID-19 Data Access Process**





## **National Leadership Team**



Philip Awadalla National Scientific Director, CanPath; Ontario Health Study



John McLaughlin Executive Director, CanPath



**Trevor Dummer** National Scientific Co-Director, CanPath;

**BC** Generations Project



Parveen Bhatti **BC** Generations Project



Shandra Harman Alberta's **Tomorrow Project** 



Jennifer Vena Alberta's Tomorrow Project



Riaz Alvi Saskatchewan PATH



**Donna Turner** The Manitoba Tomorrow Project



Philippe Broët **CARTAGENE** 



Simon Gravel **CARTAGENE** 



**Guillaume Lettre CARTAGENE** 



**Jason Hicks** Atlantic PATH

### **National Coordinating Centre**

Based at the Dalla Lana School of Public Health, University of Toronto



Dr. Philip Awadalla National Scientific Director Profile



Dr. John McLaughlin
Executive Director
Profile



Tedd Konya Project Manager Profile



Asha Mohamed
Access Officer
Profile



Arlette Bax
Communications and
Knowledge Translation Officer
Profile



Mark Bhola
Administrative Assistant
Profile



Kim Skead
National Scientific Coordinator
Profile



Treena McDonald
National Biosample
Coordinator

Profile

## **Ontario Health Study Team**

Kelly McDonald Michael Abramov Matthew Campbell Cindy Gayle Igor Koganov Ayush Lall Mason LeVon Alexis Mantell Abiola Oduwole Helen Qu Vali Radoi Sarah Salih Charles Zhu



### **Maelstrom Research**

# CanPath



Thank you to CanPath participants across the regional cohorts who generously donate their time, information and biological samples.

CanPath is a success because of the participants' ongoing commitment.

## Thank you to CanPath's sponsors and hosts!




















**Genome**Canada































